<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326518</url>
  </required_header>
  <id_info>
    <org_study_id>LUM-001</org_study_id>
    <nct_id>NCT03326518</nct_id>
  </id_info>
  <brief_title>A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44</brief_title>
  <official_title>An Open, Randomized, Controlled, Single Centre Trial to Evaluate CT Image Quality and Diagnostic Feasibility of Lumentin® 44, in Comparison With Omnipaque and Movprep.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lument AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lument AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects referred for abdominal or thoracoabdominal CT-examination will be randomised to&#xD;
      either the three contrast agents Lumentin® 44, Omnipaque® or Movprep. The difference in&#xD;
      contrast density, as observed in the CT-examination, between lumen and wall (mucosal lining)&#xD;
      will be compared by the three contrast agents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary objective reached&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Mean Difference in Contrast Density</measure>
    <time_frame>Day 1</time_frame>
    <description>difference in contrast density between lumen and wall (mucosal lining)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel Filling Properties, Extension</measure>
    <time_frame>Day 1</time_frame>
    <description>The bowel filling agent was distributed along the length of small bowel, i.e. the extension. The filling of each of the 5 selected sub-segments of the small bowel in terms of extension was examined on the CT-scan by 2 investigators, independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Extension scale:&#xD;
No sign of contrast agent&#xD;
Trace of contrast agent filling&#xD;
Segment filled to ca. 25%&#xD;
Segment filled to &gt;25% but &lt;50%&#xD;
Filled to segment filled to 50%&#xD;
Segment filled &gt; 50% but &lt;75%&#xD;
Segment filled to ca. 75%&#xD;
Segment filled to &gt;75% but &lt;100%&#xD;
Segment filled to 100% The evaluation was made by 2 independent radiology experts. The Extension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Filling Properties, Distension</measure>
    <time_frame>Day 1</time_frame>
    <description>The bowel filling agent caused a local widening of the bowel loop, distension. The filling of each of the 5 selected sub-segments of the small bowel in terms of distension was examined on the CT-scan by both the 2 investigators independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Distension scale:&#xD;
No identifiable contrast agent&#xD;
A minimal amount of contrast agent is identified&#xD;
Small amount of contrast agent, insufficient for placing a ROI of 6 mm&#xD;
Amount of contrast agent just allowing for a ROI of 6 mm&#xD;
Medium filled bowel loop&#xD;
Slightly better than grade 5&#xD;
Good filling&#xD;
Optimal filling&#xD;
Excellent or almost over distended The evaluation was made by 2 independent radiology experts. The Distension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Ability When Examining Abdominal CT</measure>
    <time_frame>Day 1</time_frame>
    <description>Diagnostic ability when examining Abd-CT was assessed on the CT-scan by the 2 investigators independently of each other.&#xD;
The following features were assessed:&#xD;
Small bowel appearance&#xD;
Parenchymal organs, i.e. Pancreas, ovaries, urinary bladder&#xD;
Mesenterium and omentum using a Likert scales of 1-9 ranging, where:&#xD;
1.Impossible to observe details&#xD;
5. Medium&#xD;
9. Excellent resolution&#xD;
The evaluation was made by 2 independent radiology experts. The Diagnostic ability score is the sum of the scores of each feature from both evaluations and hence range from 6 to 54.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degradation of Contrast Agent (Lumentin® 44)</measure>
    <time_frame>Day 1</time_frame>
    <description>Degradation of Lumentin 44 was founded on the 2 characteristics; coalescence and syneresis or drainage.&#xD;
Coalescence:&#xD;
0. No bubbles visually detectable at the CT-scan&#xD;
1. Bubbles visually detectable at the CT-scan&#xD;
Syneresis or drainage:&#xD;
0. No syneresis or drainage, i.e. separation of air and liquid phases, observed&#xD;
1. Syneresis or drainage observed Signs of degradation were assessed on the CT-scan, by both Investigator and Sub-Investigator, independently of each other, in each of the 5 selected sub-segments of the small bowel.&#xD;
The degradation of contrast agents score is the sum of the scores in each sub-segment and range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Assessment of Taste of the Contrast Agent</measure>
    <time_frame>Day 1</time_frame>
    <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Assessment of Smell of the Contrast Agent</measure>
    <time_frame>Day 1</time_frame>
    <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Assessment of Consistency of the Contrast Agent</measure>
    <time_frame>Day 1</time_frame>
    <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Assessment of Ability to Swallow the Contrast Agent</measure>
    <time_frame>Day 1</time_frame>
    <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' Assessment of Fullness After Drinking the Contrast Agent</measure>
    <time_frame>Day 1</time_frame>
    <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Subjects Referred to CT-examination of the Abdomen</condition>
  <arm_group>
    <arm_group_label>Lumentin® 44</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diluted Omnipaque®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contrast agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Movprep®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contrast agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lumentin® 44</intervention_name>
    <description>Contrast agent</description>
    <arm_group_label>Lumentin® 44</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diluted Omnipaque®</intervention_name>
    <description>Contrast agent</description>
    <arm_group_label>Diluted Omnipaque®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Movprep®</intervention_name>
    <description>Contrast agent</description>
    <arm_group_label>Movprep®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of either gender at least 18 years at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Having a clinical indication for CT-examination of the abdomen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IV administration of iodine is contraindicated&#xD;
&#xD;
          -  Known allergy to egg albumen&#xD;
&#xD;
          -  Clinical suspicion, according to medical record, of fistula formation and/or leakage&#xD;
&#xD;
          -  Referral indication of small bowel disease(s)&#xD;
&#xD;
          -  Having known manifest thyrotoxicosis&#xD;
&#xD;
          -  Having known phenylketonuria&#xD;
&#xD;
          -  Having known Glucose-6-phosphatase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Leander, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skanes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of medical imaging and function</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <results_first_submitted>May 11, 2020</results_first_submitted>
  <results_first_submitted_qc>October 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <last_update_submitted>October 3, 2020</last_update_submitted>
  <last_update_submitted_qc>October 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03326518/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lumentin® 44</title>
          <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
        </group>
        <group group_id="P2">
          <title>Diluted Omnipaque®</title>
          <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
        </group>
        <group group_id="P3">
          <title>Movprep®</title>
          <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lumentin® 44</title>
          <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
        </group>
        <group group_id="B2">
          <title>Diluted Omnipaque®</title>
          <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
        </group>
        <group group_id="B3">
          <title>Movprep®</title>
          <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>18-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65-84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>85 years and over</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Mean Difference in Contrast Density</title>
        <description>difference in contrast density between lumen and wall (mucosal lining)</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Mean Difference in Contrast Density</title>
          <description>difference in contrast density between lumen and wall (mucosal lining)</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Hounsfield units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.0" spread="192.4"/>
                    <measurement group_id="O2" value="122.1" spread="81.4"/>
                    <measurement group_id="O3" value="64.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Filling Properties, Extension</title>
        <description>The bowel filling agent was distributed along the length of small bowel, i.e. the extension. The filling of each of the 5 selected sub-segments of the small bowel in terms of extension was examined on the CT-scan by 2 investigators, independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Extension scale:&#xD;
No sign of contrast agent&#xD;
Trace of contrast agent filling&#xD;
Segment filled to ca. 25%&#xD;
Segment filled to &gt;25% but &lt;50%&#xD;
Filled to segment filled to 50%&#xD;
Segment filled &gt; 50% but &lt;75%&#xD;
Segment filled to ca. 75%&#xD;
Segment filled to &gt;75% but &lt;100%&#xD;
Segment filled to 100% The evaluation was made by 2 independent radiology experts. The Extension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Filling Properties, Extension</title>
          <description>The bowel filling agent was distributed along the length of small bowel, i.e. the extension. The filling of each of the 5 selected sub-segments of the small bowel in terms of extension was examined on the CT-scan by 2 investigators, independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Extension scale:&#xD;
No sign of contrast agent&#xD;
Trace of contrast agent filling&#xD;
Segment filled to ca. 25%&#xD;
Segment filled to &gt;25% but &lt;50%&#xD;
Filled to segment filled to 50%&#xD;
Segment filled &gt; 50% but &lt;75%&#xD;
Segment filled to ca. 75%&#xD;
Segment filled to &gt;75% but &lt;100%&#xD;
Segment filled to 100% The evaluation was made by 2 independent radiology experts. The Extension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Likert Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="21.7"/>
                    <measurement group_id="O2" value="61.2" spread="15.9"/>
                    <measurement group_id="O3" value="71.8" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Filling Properties, Distension</title>
        <description>The bowel filling agent caused a local widening of the bowel loop, distension. The filling of each of the 5 selected sub-segments of the small bowel in terms of distension was examined on the CT-scan by both the 2 investigators independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Distension scale:&#xD;
No identifiable contrast agent&#xD;
A minimal amount of contrast agent is identified&#xD;
Small amount of contrast agent, insufficient for placing a ROI of 6 mm&#xD;
Amount of contrast agent just allowing for a ROI of 6 mm&#xD;
Medium filled bowel loop&#xD;
Slightly better than grade 5&#xD;
Good filling&#xD;
Optimal filling&#xD;
Excellent or almost over distended The evaluation was made by 2 independent radiology experts. The Distension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Filling Properties, Distension</title>
          <description>The bowel filling agent caused a local widening of the bowel loop, distension. The filling of each of the 5 selected sub-segments of the small bowel in terms of distension was examined on the CT-scan by both the 2 investigators independently of each other, and graded using Likert scales between 1 and 9.&#xD;
Distension scale:&#xD;
No identifiable contrast agent&#xD;
A minimal amount of contrast agent is identified&#xD;
Small amount of contrast agent, insufficient for placing a ROI of 6 mm&#xD;
Amount of contrast agent just allowing for a ROI of 6 mm&#xD;
Medium filled bowel loop&#xD;
Slightly better than grade 5&#xD;
Good filling&#xD;
Optimal filling&#xD;
Excellent or almost over distended The evaluation was made by 2 independent radiology experts. The Distension score is the sum of the grades in each sub-segment from both evaluations and hence range from 10 to 90.</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Likert Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" spread="18.1"/>
                    <measurement group_id="O2" value="47.0" spread="12.2"/>
                    <measurement group_id="O3" value="54.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnostic Ability When Examining Abdominal CT</title>
        <description>Diagnostic ability when examining Abd-CT was assessed on the CT-scan by the 2 investigators independently of each other.&#xD;
The following features were assessed:&#xD;
Small bowel appearance&#xD;
Parenchymal organs, i.e. Pancreas, ovaries, urinary bladder&#xD;
Mesenterium and omentum using a Likert scales of 1-9 ranging, where:&#xD;
1.Impossible to observe details&#xD;
5. Medium&#xD;
9. Excellent resolution&#xD;
The evaluation was made by 2 independent radiology experts. The Diagnostic ability score is the sum of the scores of each feature from both evaluations and hence range from 6 to 54.</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Ability When Examining Abdominal CT</title>
          <description>Diagnostic ability when examining Abd-CT was assessed on the CT-scan by the 2 investigators independently of each other.&#xD;
The following features were assessed:&#xD;
Small bowel appearance&#xD;
Parenchymal organs, i.e. Pancreas, ovaries, urinary bladder&#xD;
Mesenterium and omentum using a Likert scales of 1-9 ranging, where:&#xD;
1.Impossible to observe details&#xD;
5. Medium&#xD;
9. Excellent resolution&#xD;
The evaluation was made by 2 independent radiology experts. The Diagnostic ability score is the sum of the scores of each feature from both evaluations and hence range from 6 to 54.</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Likert Scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="4.8"/>
                    <measurement group_id="O2" value="39.9" spread="5.9"/>
                    <measurement group_id="O3" value="41.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degradation of Contrast Agent (Lumentin® 44)</title>
        <description>Degradation of Lumentin 44 was founded on the 2 characteristics; coalescence and syneresis or drainage.&#xD;
Coalescence:&#xD;
0. No bubbles visually detectable at the CT-scan&#xD;
1. Bubbles visually detectable at the CT-scan&#xD;
Syneresis or drainage:&#xD;
0. No syneresis or drainage, i.e. separation of air and liquid phases, observed&#xD;
1. Syneresis or drainage observed Signs of degradation were assessed on the CT-scan, by both Investigator and Sub-Investigator, independently of each other, in each of the 5 selected sub-segments of the small bowel.&#xD;
The degradation of contrast agents score is the sum of the scores in each sub-segment and range from 0 to 10.</description>
        <time_frame>Day 1</time_frame>
        <population>Lumentin 44 is a foam containing air, and it could be suspected that the air bubbles would not withstand the condition in the stomach/intestines. Therefore, the end point Degradation of Contrast Agent was only valid for Lumentin 44 and it was included to prove the resisting power of Lumentin 44 and not to compare the IMP with Omnipaque or Movprep.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Degradation of Contrast Agent (Lumentin® 44)</title>
          <description>Degradation of Lumentin 44 was founded on the 2 characteristics; coalescence and syneresis or drainage.&#xD;
Coalescence:&#xD;
0. No bubbles visually detectable at the CT-scan&#xD;
1. Bubbles visually detectable at the CT-scan&#xD;
Syneresis or drainage:&#xD;
0. No syneresis or drainage, i.e. separation of air and liquid phases, observed&#xD;
1. Syneresis or drainage observed Signs of degradation were assessed on the CT-scan, by both Investigator and Sub-Investigator, independently of each other, in each of the 5 selected sub-segments of the small bowel.&#xD;
The degradation of contrast agents score is the sum of the scores in each sub-segment and range from 0 to 10.</description>
          <population>Lumentin 44 is a foam containing air, and it could be suspected that the air bubbles would not withstand the condition in the stomach/intestines. Therefore, the end point Degradation of Contrast Agent was only valid for Lumentin 44 and it was included to prove the resisting power of Lumentin 44 and not to compare the IMP with Omnipaque or Movprep.</population>
          <units>Scores on a scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.647" spread="0.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Assessment of Taste of the Contrast Agent</title>
        <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects' Assessment of Taste of the Contrast Agent</title>
          <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Score (1-5)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Assessment of Smell of the Contrast Agent</title>
        <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects' Assessment of Smell of the Contrast Agent</title>
          <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Score (1-5)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Assessment of Consistency of the Contrast Agent</title>
        <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects' Assessment of Consistency of the Contrast Agent</title>
          <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Score (1-5</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Assessment of Ability to Swallow the Contrast Agent</title>
        <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects' Assessment of Ability to Swallow the Contrast Agent</title>
          <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Score (1-5)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects' Assessment of Fullness After Drinking the Contrast Agent</title>
        <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
        <time_frame>Day 1</time_frame>
        <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumentin® 44</title>
            <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
          </group>
          <group group_id="O2">
            <title>Diluted Omnipaque®</title>
            <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
          </group>
          <group group_id="O3">
            <title>Movprep®</title>
            <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects' Assessment of Fullness After Drinking the Contrast Agent</title>
          <description>The subjects assessed taste on a five degree-scale:&#xD;
Very negative&#xD;
Negative&#xD;
Neutral&#xD;
Positive&#xD;
Very positive</description>
          <population>Two patients in the Lumentin group withdrew prior to contrast agent intake and were withdrawn from the efficacy analysis.</population>
          <units>Score (1-5)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lumentin® 44</title>
          <description>Contrast agent&#xD;
Lumentin® 44: Contrast agent</description>
        </group>
        <group group_id="E2">
          <title>Diluted Omnipaque®</title>
          <description>Contrast agent&#xD;
Diluted Omnipaque®: Contrast agent</description>
        </group>
        <group group_id="E3">
          <title>Movprep®</title>
          <description>Contrast agent&#xD;
Movprep®: Contrast agent</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Thomas Fork</name_or_title>
      <organization>Lument AB</organization>
      <phone>+46 705336996</phone>
      <email>thomas.fork@lumentab.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

